Wednesday, August 04, 2010 4:28:52 PM
Covidien Ltd. F3Q10 (Qtr End 6/30/10 Earnings Call Transcript
Rick Wise - Swanson
And just as a quick followup to that, is this something that you address to try to offset and improve over the next couple of years, you address totally internally, or does this raise the greater likelihood that you’ll try to seek some technology products externally? Thanks.
Chuck Dockendorff Covidien
Sure. We don’t comment specifically on M&A. But I think what you’ve seen in the past with pharma, what we’ve done is built up a nice clinical regulatory, scientific capability. We know have a sales force in this controlled-substance area. I think there will be other opportunities to do the kind of licensing deals that will bring in new product opportunities where we can leverage our skills in those areas I just mentioned, as well as our sales force.
I like our strategy, and I think that’s where you’ll see our strategy continue to focus from a growth standpoint.
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM
Integrated Ventures Announces Partnership And Lease Agreement with Driptide Wellness - Leading Health and Wellness Provider. • INTV • Oct 29, 2024 8:45 AM